Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

Citation data:

Bone, ISSN: 1873-2763, Vol: 105, Page: 11-17

Publication Year:
2017
Usage 67
Abstract Views 37
Clicks 28
Link-outs 2
Captures 65
Readers 64
Exports-Saves 1
Social Media 89
Tweets 77
Shares, Likes & Comments 12
Citations 26
Citation Indexes 26
PMID:
28789921
DOI:
10.1016/j.bone.2017.08.003
Author(s):
Tsourdi, Elena; Langdahl, Bente; Cohen-Solal, Martine; Aubry-Rozier, Bérengere; Eriksen, Erik Fink; Guañabens, Nuria; Obermayer-Pietsch, Barbara; Ralston, Stuart H; Eastell, Richard; Zillikens, M Carola
Publisher(s):
Elsevier BV
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
review description
The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is not suppressed after its cessation. Recent reports imply that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures.